anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, in particular, cosmetology; may be used for reduction of mimic wrinkles. SUBSTANCE: method includes introduction of botulin neurotoxin of A type in the amount not more than 100 units per procedure. Preparation is punctuatedly introduced in relaxed mimic muscle at the rate not more than 5 units of preparation in one point and not more than 50 units per region of one wrinkle of patient being in vertical position. Interval between procedures is not more than 3 months. Treatment is required 2-4 procedures per year. Botulin neurotoxin may be introduced in muscles formed intereyebrow and periorbital wrinkles, and also in horizontal wrinkles in the region of forehead. EFFECT: stable effect up to 6 months. 5 cl
PURPOSE: A composition for skin cell regeneration and a cosmetic composition using the same are provided to be simply produced using embryo stem cells and to effectively regenerate skin cells. CONSTITUTION: A method for producing a composition for regenerating skin cells comprises: a step of sub-culturing embryoid derived from embryonic stem cells to form differentiated cells; a step of culturing the differentiated cells; and a step of collecting a solution ingredient. The composition for regenerating stem cells contains the solution ingredient. The solution ingredient contains a growth factor and procollagen. The solution ingredient further contains free amino acid. The growth factor contains vascular endothelial growth factor and fibroblast growth factor.
This study is a phase II, 5 arm study with a 12 week active dosing period. The study will be conducted in 2 stages. In the first stage, the first 6 women to be enrolled will be treated at the 12mg dose level, and in addition to the other required study assessments will be monitored with a 24-hour PK assessment on Day 14, and daily trough assessments for the first 14 days. If, at Visit 3, the Cmax or AUC of any subject treated at 12mg exceeds the mean observed for the highest safe oral dose administered in the ZP-204 study, all subjects enrolled at the 12mg level will be discontinued, no further patients will be treated at this dose level, and the 6mg vaginal dose will be assessed in a similar fashion. In the second stage, the remaining subjects will be randomized to a dose of 3, 6, 12 or 24 mg.

For all subjects there will be a 4-6 week placebo run-in period, to establish baseline parameters (bleeding and quality of life) followed by treatment at one of three single-blind Proellex doses (3, 6 or 12 mg daily, administered vaginally in capsule form.) The primary efficacy endpoint will be bleeding assessed using the Pictorial Blood Loss Assessment Chart (PBAC) after 12 or 16 weeks of treatment. The secondary endpoints will be changes in size of uterine fibroids assessed by MRI and improvement in quality of life assessed using the Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFSQOL0. Safety endpoints include significant adverse events, changes in physical examination results, and/or clinical laboratory results significantly outside of normal range. For subjects enrolled in Stage 2, PK will be assessed after the first and last doses and trough levels every 2 weeks.
Clinical experience with tyrosine kinase inhibitors (TKIs) over the past two decades has shown that, despite the apparent therapeutic benefit, nearly 30% of patients with chronic myelogenous leukemia (CML) display primary resistance or intolerance to TKIs, and approximately 25% of those treated are forced to switch TKIs at least once during therapy due to acquired resistance. Safe and effective treatment modalities targeting leukemic clones that escape TKI therapy could hence be game changers in the professional management of these patients. Here, we aimed to investigate the efficacy of a novel therapeutic oligonucleotide of unconventional design, called ASP210, to reduce BCR-ABL1 mRNA levels in TKI-resistant CML cells, with the assumption of inducing their apoptosis. Imatinib- and dasatinib-resistant sublines of BCR-ABL1-positive MOLM-7 and CML-T1 cells were established and exposed to 0.25 and 2.5 µM ASP210 for 10 days. RT-qPCR showed a remarkable reduction of the target mRNA level by >99% after a single application. Cell viability was monitored daily by trypan blue staining. In response to the lack of driver oncoprotein BCR-ABL1, TKI-resistant CML cells underwent apoptosis regardless of the presence of the clinically relevant T315I mutation by day 5 after redosing with ASP210. The effect was selective for cancer cells, indicating a favorable safety profile for this therapeutic modality. Furthermore, the spontaneous uptake and high intracellular concentrations of ASP210 suggest its potential to be effective at relatively low doses. The present findings suggest that ASP210 is a promising therapeutic avenue for patients with CML who fail to respond to TKI therapy.NEW & NOTEWORTHY Effective treatment modalities targeting leukemic clones that escape tyrosine kinase inhibitor (TKI) therapy could be game changers in the professional management of patients displaying primary resistance, intolerance, or acquired resistance to TKIs. Although delivering authentic innovations today is more complex than ever, we developed a highly potent and safe oligonucleotide-based modality against BCR-ABL1 mRNA named ASP210 that effectively induces cell death in BCR-ABL1-positive TKI-resistant cells while sparing BCR-ABL1-negative healthy cells.
The invention relates to a method for forming dental impressions using an impression tray (1, 2) having a groove-shaped mould case (15). In an individualisation process step preceding preparation of the impression, a highly viscous curable impression material (11) is applied around the edges (4, 3) of the impression tray, and the impression tray is then pressed with its edges against the mobile mucous membrane. After curing of the highly viscous impression material the impression tray is removed from the jaw together with the impression material. In a subsequent process step, the mould case of the impression tray, which has previously been fully individualised, is filled with a curable impression material of low viscosity, and the impression tray is then pressed onto the jaw with its edges resting against the mobile mucous membranes. The patient is instructed to mobilise the mobile mucous membranes. After curing of the impression material of low viscosity whose maximum final hardness is 30 Shore A the fully individualised impression tray is removed from the jaw together with the impression material. The grooved bottom of the mould case of the impression tray which has previously been fully individualised can be lined with a curable, kneadable material. …<IMAGE>…
Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and 2 doses of Menjugate® vaccine in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with Menjugate® vaccine at Day 0. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
Stress-induced childhood-onset neurodegeneration with variable ataxia and seizures (CONDSIAS) is an extremely rare, autosomal recessive neurodegenerative disorder. It is caused by biallelic pathogenic variants in the ADPRS gene, which encodes an enzyme involved in DNA repair, and is characterized by exacerbations in relation to physical or emotional stress, and febrile illness. We report a 24-year-old female, who was compound heterozygous for two novel pathogenic variants revealed by whole exome sequencing. Additionally, we summarize the published cases of CONDSIAS. In our patient, onset of symptoms occurred at 5 years of age and consisted of episodes of truncal dystonic posturing, followed half a year later by sudden diplopia, dizziness, ataxia, and gait instability. Progressive hearing loss, urinary urgency, and thoracic kyphoscoliosis ensued. Present neurological examination revealed dysarthria, facial mini-myoclonus, muscle weakness and atrophy of hands and feet, leg spasticity with clonus, truncal and appendicular ataxia, and spastic-ataxic gait. Hybrid [18F]-fluorodeoxyglucose (FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) of the brain revealed cerebellar atrophy, particularly of the vermis, with corresponding hypometabolism. MRI of the spinal cord showed mild atrophy. After informed consent from the patient, we initiated experimental, off-label treatment with minocycline, a poly-ADP-polymerase (PARP) inhibitor, which has shown beneficial effects in a Drosophila fly model. The present case report expands the list of known pathogenic variants in CONDIAS and presents details of the clinical phenotype. Future studies will reveal whether PARP inhibition is an effective treatment strategy for CONDIAS.
To provide a medication guidance system and a server that enable an online guidance of medications.SOLUTION: A terminal 11 for a pharmacist is used by a pharmacist 30. A terminal 12 for a patient is used by a patient 50. A terminal 13 for a medical facility is used by a medical facility 40. A server 15 can communicate with the terminals 11, 12, and 13. The terminal 13 for a medical facility sends an electric prescription to the server 15. The server 15 receives an electronic prescription from the terminal 13 for a medical facility. The server 15 receives an input of a prescription number from the terminal 12 for a patient. The server 15 allows the pharmacist 30 and the patient 50 to face each other by the terminals 11 and 12 to give a guidance for medication from the pharmacist 30, after the prescription number received by the terminal 12 for a patient agrees with the prescription number of the electric prescription received by the terminal 13 for a medical facility.SELECTED DRAWING: Figure 1
The invention relates to an oral composition of anticancer chemotherapeutic preparations. A formula for the composition comprises active components consisting of chemotherapeutic drugs like taxanes, Omega-3 aliphatic acid, dietary fiber, etc., and further comprises adjuvant components. The gastric-soluble and enteric capsules and sublingual and buccal tablets of the oral composition are used for local or targeted drug delivery for different diseases, greatly improve curative effect and lower toxic and side effect. The oral composition overcomes the problems of toxicity and curative effect of a drug delivery system like an injection. Moreover, an oral dosage form is simpler; the dosage and time of oral administration can be easily adjusted; the treatment concentrations of chemotherapeutic drugs like taxane active substances are easily to regulate and control; and the concentrations of taxanes can be maintained at an effective treatment concentration and be lower than toxic concentration in a treatment period. Compared with taxanes in the dosage form of an injection in the prior art, the oral composition provided by the invention achieves the purposes of long-term administration and continuous treatment; so the impact therapy that treatment should be suspended after a certain treatment course and be resumed after recovery of muscle power.
1. Technical Result Increase in therapeutic potential of the polypeptides.                     2. Essence Compounds are disclosed having the general formula R1-X-R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or different. Preferred R1 and R2 groups are interleukin-1 receptor antagonist, 30kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. The method for production of the mentioned compounds is provided. The pharmaceutical compositions and their use are provided.          3. Field of Application Medicine, in particular therapy.
As dexamethasone is an inexpensive and commonly used medication, it would be beneficial to know if a similar prolongation of analgesia occurs when a local anesthetic is given neuraxially in combination with low dose intravenous dexamethasone. This project will investigate the efficacy of low dose intravenous (IV) dexamethasone in prolonging the duration of post operative analgesia provided by an intraoperative caudal injection of local anesthetic. All patients will be enrolled in the study the day of surgery, in the preoperative waiting area. The study will be explained by an anesthesiologist with extensive knowledge of the protocol. Computer randomization will occur for each patient. Randomization will not increase the risk to either group as all medications and techniques utilized for this study are commonly accepted for routine care for these patients.
Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; "Hilfe zur Erziehung") in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan ("Hilfeplan"). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS.
BACKGROUND: Although sleep quality (SQ) reportedly affects the health-related quality of life (QOL) of patients with epilepsy, little is known about the potential association between SQ and QOL, particularly in children with epilepsy (CWE). Our study aimed to investigate the mediating effect of SQ on the QOL of CWE to obtain more information for the prevention and treatment of epilepsy in children.
METHODS: We collected general demographic and clinical data of 212 CWE and 79 controls (children who visited the Health Examination Department), and their guardians were instructed to answer the Children's Sleep Habits Questionnaire (CSHQ) and the optimized Quality of Life in Childhood Epilepsy Questionnaire-16 (QOLCE-16). The t-test, analysis of variance, chi-square test, and Fisher's exact test were used for between group comparisons. The Pearson correlation was used to analyze the correlation between variables. The direct, indirect, and total effects of predictors on the QOL of CWE were estimated based on an adjusted mediation model.
RESULTS: CWE had significantly smaller long-term urban residence rates, less educated guardians, higher total CSHQ score, higher incidence of poor SQ, higher bedtime resistance, more sleep anxiety, worse sleep-disordered breathing, increased parasomnia, more daytime sleepiness, more frequent night waking, and greater sleep onset delay than controls (P < 0.05 for all). The univariable analysis showed significant differences in total CSHQ scores between CWE with different seizure frequency in the last month, whether or not drug-resistant epilepsy (DRE), and with different video electroencephalogram (VEEG) findings (P < 0.05 for all). Differences in QOLCE-16 scores between CWE with different guardian's employment status, age at diagnosis, number of anti-seizure medication (ASM) types, seizure frequency in the last month, DRE status, seizure type, VEEG findings, neuropsychological evaluation findings, magnetic resonance imaging (MRI) findings, and etiology were statistically significant (P < 0.05 for all). The correlation study indicated that the total CSHQ score was negatively correlated with the QOLCE-16 score (P < 0.05). The mediation analysis showed that DRE and VEEG abnormalities had a standardized direct effect on the QOL. Seizure frequency in the last month, DRE, and VEEG abnormalities had an indirect effect on the QOL through SQ, and their mediating effect values of SQ were 31.61 %, 13.45 %, and 14.35 %, respectively.
CONCLUSION: Our findings uncovered the relationship of some clinical characteristics with SQ and QOL and characterized the nature of factors affecting the QOL of CWE. SQ could be a key factor in the prognosis of CWE experiencing epileptic seizures, and more attention should be paid on the management of SQ in interventions for epilepsy.
The present invention provides a formulation and method for preparing specific T cells, and a method for fabricating the formulation is also disclosed. The formulation can induce specific T cell responses, and comprises at least a cell population of dendritic killer cells presenting specific antigens. In addition, the method mentioned above for preparing specific T cells comprises following steps. A T cell population is provided, and then a formulation of preparing specific T cells is mixing with the T cell population. After cultivating, the specific T cells are harvested. Furthermore, the method for fabricating the above formulation comprises the following steps. First, a cell population of dendritic killer cells is provided. A target sample is then provided, and a step of making the cell population of the dendritic killer cells is co-cultivated with the target sample. After co-cultivating, a cell population of dendritic killer cells presenting specific antigens is harvested.
Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4+ T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28. 

MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-Ɣ, IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection.  


Overall, the effect of MPA is cytostatic and reversible.
Chronic liver disease leads to hepatocellular injury that triggers a pro-inflammatory state in several parenchymal and non-parenchymal hepatic cell types, ultimately resulting in liver fibrosis, cirrhosis, portal hypertension and liver failure. Thus, an improved understanding of inflammasomes - as key molecular drivers of liver injury - may result in the development of novel diagnostic or prognostic biomarkers and effective therapeutics. In liver disease, innate immune cells respond to hepatic insults by activating cell-intrinsic inflammasomes via toll-like receptors and NF-κB, and by releasing pro-inflammatory cytokines (such as IL-1β, IL-18, TNF-α and IL-6). Subsequently, cells of the adaptive immune system are recruited to fuel hepatic inflammation and hepatic parenchymal cells may undergo gasdermin D-mediated programmed cell death, termed pyroptosis. With liver disease progression, there is a shift towards a type 2 inflammatory response, which promotes tissue repair but also fibrogenesis. Inflammasome activation may also occur at extrahepatic sites, such as the white adipose tissue in MASH (metabolic dysfunction-associated steatohepatitis). In end-stage liver disease, flares of inflammation (e.g., in severe alcohol-related hepatitis) that spark on a dysfunctional immune system, contribute to inflammasome-mediated liver injury and potentially result in organ dysfunction/failure, as seen in ACLF (acute-on-chronic liver failure). This review provides an overview of current concepts regarding inflammasome activation in liver disease progression, with a focus on related biomarkers and therapeutic approaches that are being developed for patients with liver disease.
PURPOSE: To obtain a veterinary synergistic medicine containing polymyxin B or an acid adduct salt thereof, chlotrimazole or chloroquinaldol and useful for the treatment of mastitis and uteritis in an live stock. CONSTITUTION: This veterinary synergistic medicine contains 1 pt.wt. polymyxin B or pharmaceutically permissible acid adduct thereof, 1-1,000 pt.wt. chlotrimazole: 1-(2-chlorophenyl) diphenylmethyl-1H-imidazole or 1-400 pt.wt. chloroquinaldol: 2-methyl-5,7-dichloro-8-hydroxyquinoline together with a usually used carrier or additive. The medicine is effective by a small amount of administration and in addition, has a wide antibacterial spectrum affecting both bacteria and fungi.
Compound containing at least 15% inorganic content demonstrates liquid-like behavior and is distinct in exhibiting liquid-like behavior in the absence of solvent. In one case it is quaternary ammonium derivative of a heteropolyacid. In another case, it is a salt formed by reaction of heteropolyacid and polyethylene glycol alkylamine. In other cases, it is condensation product of oxide and quaternary ammonium cation where the balancing anion has a molecular weight greater than 200. In still other cases it is a salt formed by reaction of sulfonated silica or sulfonated fullerene and polyethylene glycol alkylamine. In still other cases, it is a neutral organic-inorganic hybrid which is PEG-functionalized silica nanoparticle or is a layered-nanoparticle obtained by hydrolytic polymerization of organosilane in nonpolar solvent.